Imipenem Monohydrate

This article explores the use of Imipenem Monohydrate in various clinical trials. Imipenem Monohydrate is an antibiotic used to treat serious bacterial infections. The trials discussed here investigate its effectiveness in treating conditions like ventilator-associated pneumonia, complicated urinary tract infections, and its potential for kidney protection during certain medical procedures.

Table of Contents

What is Imipenem Monohydrate?

Imipenem Monohydrate is a powerful antibiotic medication used to treat serious bacterial infections[1]. It belongs to a class of antibiotics called carbapenems, which are considered “last resort” antibiotics for treating severe or resistant infections. Imipenem is typically combined with another drug called cilastatin, which helps prevent the breakdown of imipenem in the kidneys, allowing it to remain active in the body longer[2].

How Does Imipenem Work?

Imipenem works by interfering with the cell wall synthesis of bacteria. This action prevents bacteria from growing and multiplying, ultimately leading to their death. The broad spectrum of activity of imipenem makes it effective against many types of bacteria, including both gram-positive and gram-negative organisms[1].

What Conditions Does Imipenem Treat?

Imipenem is used to treat a variety of serious bacterial infections, including:

  • Ventilator-associated pneumonia (VAP): A type of lung infection that occurs in patients who are on mechanical ventilation[1]
  • Complicated urinary tract infections (cUTI): Severe infections of the urinary system that may involve the kidneys[3]
  • Acute pyelonephritis: A serious kidney infection[3]
  • Intra-abdominal infections: Infections within the abdomen, such as peritonitis
  • Skin and soft tissue infections: Severe infections of the skin and underlying tissues
  • Septicemia: A life-threatening condition where bacteria enter the bloodstream

Imipenem is often used when other antibiotics have failed or when infections are caused by bacteria resistant to other treatments[2].

How is Imipenem Administered?

Imipenem is typically given as an intravenous (IV) infusion in a hospital setting. It is administered directly into the bloodstream through a vein. The medication is usually given every 6 to 8 hours, depending on the severity of the infection and the patient’s kidney function[2][3].

Dosage Information

The dosage of imipenem varies depending on the type and severity of infection, as well as the patient’s age, weight, and kidney function. Typical adult dosages range from 1 to 4 grams per day, divided into multiple doses[2][3]. The duration of treatment can range from 5 to 14 days or longer, depending on the infection being treated and the patient’s response.

Potential Side Effects

Like all medications, imipenem can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Rash or itching
  • Injection site reactions (pain, swelling, or redness)

More serious side effects, though rare, can include severe allergic reactions, seizures, and Clostridioides difficile infection (a type of severe diarrhea)[1]. It’s important to report any unusual symptoms to your healthcare provider immediately.

Precautions and Contraindications

Imipenem should be used with caution in certain populations. It is contraindicated (should not be used) in patients with:

  • Known allergy to imipenem, cilastatin, or other carbapenems
  • Severe kidney dysfunction (without hemodialysis)
  • History of seizures or central nervous system disorders
  • Pregnancy or breastfeeding (unless the benefits outweigh the risks)

Patients with a history of allergies to other beta-lactam antibiotics (such as penicillins or cephalosporins) should be monitored closely when receiving imipenem[1][3].

Ongoing Research

Imipenem continues to be studied in clinical trials to evaluate its effectiveness in various infections and to compare it with other antibiotics. For example, a current study is comparing the efficacy of imipenem/cilastatin to newer antibiotics like cefepime/nacubactam and aztreonam/nacubactam in treating complicated urinary tract infections and acute pyelonephritis[3]. Another study is investigating the potential of cilastatin (one component of the imipenem/cilastatin combination) to protect against kidney damage in patients undergoing certain types of chemotherapy[4].

These ongoing studies highlight the continued importance of imipenem in treating serious bacterial infections and the potential for expanding its use in other medical contexts.

Aspect Details
Main Uses in Trials Treatment of ventilator-associated pneumonia, complicated urinary tract infections, acute pyelonephritis
Administration Method Intravenous infusion
Dosage Range Up to 4g daily, with total treatment doses ranging from 24g to 84g
Treatment Duration Varies by study, typically 6-14 days
Combination Therapy Often combined with cilastatin for kidney protection
Novel Applications Potential use of cilastatin for kidney protection during chemotherapy
Study Types Randomized, double-blind, multicenter trials; comparator in studies of new antibiotics

Ongoing Clinical Trials on Imipenem Monohydrate

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    3 1 1 1
    Spain
  • Study Comparing Cilastatin and Sodium Thiosulfate for Kidney Protection in Patients Undergoing Surgery with Chemotherapy Using Cisplatin

    Recruiting

    2 1 1 1
    Investigated diseases:
    Spain
  • Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

    Not recruiting

    3 1 1 1
    Bulgaria Czechia Estonia Latvia Lithuania Slovakia
  • Study on the Effectiveness of Co-Trimoxazole for Treating Ventilator-Associated Pneumonia in ICU Patients Compared to a Drug Combination

    Not recruiting

    3 1 1 1
    France

Glossary

  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Complicated Urinary Tract Infection (cUTI): A urinary tract infection that has additional factors making it more difficult to treat, such as structural abnormalities or catheterization.
  • Acute Pyelonephritis: A sudden and severe kidney infection.
  • Intravenous Infusion: A method of delivering medications directly into a vein over a period of time.
  • Cilastatin: A drug often combined with Imipenem to prevent its breakdown in the kidneys, allowing more of the antibiotic to reach the infection site.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • HIPEC: Hyperthermic Intraperitoneal Chemotherapy, a cancer treatment that involves heating chemotherapy drugs and delivering them directly into the abdominal cavity.
  • Acute Kidney Injury: A sudden episode of kidney failure or kidney damage that happens within a few hours or days.
  • KDIGO Scale: Kidney Disease: Improving Global Outcomes, a scale used to classify the severity of acute kidney injury.
  • Cytoreductive Surgery: A surgical procedure to remove as much visible cancer as possible from the abdominal area.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-co-trimoxazole-for-treating-ventilator-associated-pneumonia-in-icu-patients-compared-to-a-drug-combination/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-7-vs-14-days-of-antibiotic-treatment-with-meropenem-for-patients-with-pseudomonas-aeruginosa-blood-infection/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cefepime-nacubactam-and-aztreonam-nacubactam-for-adults-with-complicated-urinary-tract-infections-or-acute-pyelonephritis/
  4. http://clinicaltrials.eu/trial/study-comparing-cilastatin-and-sodium-thiosulfate-for-kidney-protection-in-patients-undergoing-surgery-with-chemotherapy-using-cisplatin/